Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brinzolamide 1% AZOPT · 1 trial · 2 indications
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) was used for the analysis.
| Arm | Type | Description |
|---|---|---|
| TravA/Brinz | EXPERIMENTAL | Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| TravB/Brinz | EXPERIMENTAL | Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| TravC/Brinz | EXPERIMENTAL | Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| AZOPT | ACTIVE_COMPARATOR | Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks |
| TRAV Z | ACTIVE_COMPARATOR | Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| TRAV Z + AZOPT | ACTIVE_COMPARATOR | Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| Name | Type | Description |
|---|---|---|
| Dose Level A / Brinzolamide 1% ophthalmic suspension | DRUG | Fixed combination |
| Dose Level B / Brinzolamide 1% ophthalmic suspension | DRUG | Fixed combination |
| Dose Level C / Brinzolamide 1% ophthalmic suspension | DRUG | Fixed combination |
| Brinzolamide 1% ophthalmic suspension AZOPT® | DRUG | - |
| Travoprost 0.004% ophthalmic solution TRAVATAN Z® | DRUG | - |
| Travoprost solution vehicle | DRUG | Inactive ingredients used for masking purposes |
| Brinzolamide suspension vehicle | DRUG | Inactive ingredients used for masking purposes |
Inclusion Criteria: * Diagnosed with open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) or ocular hypertension; * IOP within the protocol-specified range at both the Eligibility 1 and 2 Visits. Mean IOP must not be \>36 mmHg at any time point; * Able to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Brinzolamide 1% AZOPT is used for glaucoma, specifically in the treatment of open-angle glaucoma or ocular hypertension. It is an ophthalmic suspension being studied as a combination therapy with travoprost. The drug is administered to lower intraocular pressure in patients with these conditions.
Brinzolamide 1% AZOPT is developed by Alcon Inc., a company traded on the stock exchange under the ticker symbol ALC. Alcon is the developer of this investigational ophthalmic product, which is currently in clinical development for the treatment of glaucoma.
Brinzolamide 1% AZOPT is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for the treatment of glaucoma and ocular hypertension.
Brinzolamide 1% AZOPT is associated with one completed clinical trial, NCT02140060, a Phase 2 proof-of-concept study. This 6-week study evaluated travoprost/brinzolamide ophthalmic suspension in 327 participants with open-angle glaucoma or ocular hypertension. The trial was randomized, double-blind, and active-controlled.
Brinzolamide 1% AZOPT is a component of the combination product travoprost/brinzolamide ophthalmic suspension. The clinical trial NCT02140060 studied this combination, which includes brinzolamide 1% (AZOPT) along with travoprost. The study was designed to evaluate the efficacy of this fixed-dose combination in lowering intraocular pressure.